MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Race/ethnicity

Search medical newsFind research, conditions and clinical updates
  • Home
  • Race/ethnicity
Systemic Therapies for Pediatric Moderate-to-Severe Atopic Dermatitis: Comparative Outcomes Across Skin Colors from the PEDISTAD Registry
Posted inDermatology news Pediatrics

Systemic Therapies for Pediatric Moderate-to-Severe Atopic Dermatitis: Comparative Outcomes Across Skin Colors from the PEDISTAD Registry

Posted by By MedXY 10/02/2026
This analysis of the 4-year PEDISTAD registry reveals dupilumab’s superior effectiveness and comparable safety in treating moderate-to-severe atopic dermatitis in children across diverse racial groups.
Read More
Rethinking Race/Ethnicity in Cardiovascular Risk Assessment: The Race-Free MESA Risk Score
Posted inCardiology news Public Health

Rethinking Race/Ethnicity in Cardiovascular Risk Assessment: The Race-Free MESA Risk Score

Posted by By MedXY 08/07/2026
A race-free adaptation of the MESA risk score estimates 10-year coronary heart disease risk with comparable accuracy to the original, challenging the necessity of including race/ethnicity in cardiovascular risk prediction.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Advancing Diagnosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights from the LITMUS Multicentre Study
  • Reducing Post-PICU Acute Care through Early Primary Care Follow-Up: Evidence from Pediatric Hospitalizations
  • Targeting IL-4 Receptor-α in Localised Scleroderma: Promising Phase 2 Evidence for Fibrosis Modulation
  • Optimizing Outcomes in Uterus Transplantation: Comprehensive Living Donor Evaluation from the Dallas Program
  • Decoding Systemic Sclerosis: A New Vascular-Fibrotic Framework for Risk Stratification
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top